Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 2Completed 2Active not recruiting 2Unknown 1Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Neoplasm Metastasis 25Leukemia, Myeloid, Acute 25Breast Neoplasms 18Prostatic Neoplasms 16Myelodysplastic Syndromes 15Lymphoma, Large B-Cell, Diffuse 15Leukemia, Lymphocytic, Chronic, B-Cell 15Multiple Myeloma 14Lung Neoplasms 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Colorectal Neoplasms 12Carcinoma, Non-Small-Cell Lung 12Triple Negative Breast Neoplasms 11Pancreatic Neoplasms 11Burkitt Lymphoma 11Neoplasms 9Lymphoma, Mantle-Cell 9Leukemia, Myelomonocytic, Chronic 9Ovarian Neoplasms 8Melanoma 8Stomach Neoplasms 7Lymphoma, T-Cell 7Squamous Cell Carcinoma of Head and Neck 6Lymphoma, B-Cell 6Carcinoma, Renal Cell 6Myeloproliferative Disorders 5Mouth Neoplasms 5Lymphoma 5Leukemia, Biphenotypic, Acute 5Fallopian Tube Neoplasms 5

Interventions

Specimen Handling 3Azacitidine 3ruxolitinib 2Melphalan 2Cyclophosphamide 2Busulfan 2Biopsy 2venetoclax 1posaconazole 1onvansertib 1merphos 1gilteritinib 1fludarabine phosphate 1fludarabine 1fedratinib 1axatilimab 1Whole-Body Irradiation 1Watchful Waiting 1Tranexamic Acid 1Tacrolimus 1Succimer 1Stem Cell Transplantation 1Rituximab 1Positron-Emission Tomography 1Pentetic Acid 1Methotrexate 1Janus Kinase Inhibitors 1Injections 1Hyperbaric Oxygenation 1High-Energy Shock Waves 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Myelodysplastic-Myeloproliferative Diseases × Biopsy × Clear all
NCT06523556 2026-03-13

Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia

Ohio State University Comprehensive Cancer Center

Phase 1/2 Recruiting
52 enrolled
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT05549661 2026-02-23

Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms

Mayo Clinic

Phase 1 Recruiting
25 enrolled
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡